Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ

Business

FILE PHOTO: Switzerland’s national flag flies in front of the logo of Swiss drugmaker Novartis in Basel, Switzerland, January 30, 2019. REUTERS/Arnd Wiegmann/File Photo

(Reuters) – Swiss drugmaker Novartis AG (NOVN.S) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (MDCO.O) for about $7 billion, the Wall Street Journal reported on Saturday.

The deal, in which Novartis has agreed to pay $85 a share, could be announced this weekend, the Journal reported, citing people familiar with the matter.

Neither Novartis nor The Medicines Co were immediately available for comment on Saturday.

Reporting by Kanishka Singh in Bengaluru; editing by Jonathan Oatis

Products You May Like

Articles You May Like

Cold snap sees parts of the East wake up to snow
H&R Block, Intuit stocks fall following Trump tax-filing app report
‘Hello, Love, Again’ Sets Opening Record For Filipino Film, Marketing To Vibrant Audience “Exhibitors May Have Underestimated”
Water companies blocked from using customer cash for ‘undeserved’ bonuses | Money News
‘You Can’t Be Surprised the White African Guy’s First Idea Is Slavery’